Research Article

Polymeric micelles of suberoylanilide hydroxamic acid to enhance the anticancer potential in vitro and in vivo

Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Shameerpet, Hyderabad, Telangana 500078, India

^‡These authors contributed equally and should be considered first authors

Search for more papers by this author

Prakruti Trivedi^‡

Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Shameerpet, Hyderabad, Telangana 500078, India

^‡These authors contributed equally and should be considered first authors

Search for more papers by this author

Preeti Kumari

Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Shameerpet, Hyderabad, Telangana 500078, India

Search for more papers by this author

Pratyusha Ghanta

Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Shameerpet, Hyderabad, Telangana 500078, India

Search for more papers by this author

Balaram Ghosh

Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Shameerpet, Hyderabad, Telangana 500078, India

Search for more papers by this author

Swati Biswas

*Author for correspondence:

E-mail Address: swati.biswas@hyderabad.bits-pilani.ac.in

Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Shameerpet, Hyderabad, Telangana 500078, India

Search for more papers by this author

Published Online:23 Nov 2016https://doi.org/10.2217/nnm-2016-0321

View article

Abstract

Aim: To improve the bioavailability and anticancer potential of suberoylanilide hydroxamic acid (SAHA) by developing a drug-loaded polymeric nanomicellar system. Methods: SAHA-loaded Poly(ethylene glycol)-block-poly(caprolactone) (PEG-PCL) micelles were developed, and physico-chemically characterized. In vitro cellular uptake, viability and apoptosis-inducing ability of the SAHA-PEG-PCL micelles were investigated. In vivo anticancer activity was evaluated in C57BL/6 mice-bearing tumor. Results: The SAHA-PEG-PCL micelles had optimum size (∼130 nm) with an entrapment efficiency of approximately 67%. The SAHA-PEG-PCL induced stronger cell cycle arrest in G2/M phase leading to higher rate of apoptosis compared to free SAHA. SAHA-PEG-PCL demonstrated significant tumor suppression compared to free SAHA in vivo. Conclusion: The physicochemical properties and the antitumor efficacy of SAHA were improved by encapsulating in polymeric micelles.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1 Thun MJ, Delancey JO, Center MM, Jemal A, Ward EM. The global burden of cancer: priorities for prevention. Carcinogenesis 31(1), 100–110 (2010).
Medline CASGoogle Scholar
2 Global Burden of Disease Cancer Collaboration. Fitzmaurice C, Dicker D et al. The global burden of cancer 2013. JAMA Oncol. 1(4), 505–527 (2015).
MedlineGoogle Scholar
3 Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74(11), 2913–2921 (2014).
Medline CASGoogle Scholar
4 Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 13(9), 673–691 (2014). •• Discussed the role of histone deacetylases in cancer and various mechanisms of action of histone deacetylases inhibitors.
Medline CASGoogle Scholar
5 Sankar R, Karthik S, Subramanian N, Krishnaswami V, Sonnemann J, Ravikumar V. Nanostructured delivery system for Suberoylanilide hydroxamic acid against lung cancer cells. Mater. Sci. Eng. C Mater. Biol. Appl. 51, 362–368 (2015).
Medline CASGoogle Scholar
6 Kroesen M, Büll C, Gielen PR et al. Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma. OncoImmunology 5(6), e1164919 (2016).
MedlineGoogle Scholar
7 West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest. 124(1), 30–39 (2014).
Medline CASGoogle Scholar
8 Mottamal M, Zheng S, Huang T, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules 20(3), 3898 (2015).
Medline CASGoogle Scholar
9 Katoch O, Dwarakanath B, Agrawala PK. HDAC inhibitors: applications in oncology and beyond. HOAJ Biol. 2(1), (2013).
Google Scholar
10 Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 27(32), 5459–5468 (2009).
Medline CASGoogle Scholar
11 Siegel D, Hussein M, Belani C et al. Vorinostat in solid and hematologic malignancies. J. Hematol. Oncol. 2(1), 1–11 (2009).
MedlineGoogle Scholar
12 Nihal M, Roelke CT, Wood GS. Anti-melanoma effects of vorinostat in combination with polyphenolic antioxidant (−)-epigallocatechin-3-gallate (EGCG). Pharm. Res. 27(6), 1103–1114 (2010).
Medline CASGoogle Scholar
13 Kwak TW, Kim DH, Jeong Y-I, Kang DH. Antitumor activity of vorinostat-incorporated nanoparticles against human cholangiocarcinoma cells. J. Nanobiotech. 13(1), 1–13 (2015).
MedlineGoogle Scholar
14 Kim JY, Shim G, Choi HW et al. Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex. Biomaterials 33(17), 4424–4430 (2012).
Medline CASGoogle Scholar
15 Teicher BA. Combinations of PARP, hedgehog and HDAC inhibitors with standard drugs. Curr. Opin. Pharmacol. 10(4), 397–404 (2010).
Medline CASGoogle Scholar
16 Tran TH, Ramasamy T, Truong DH et al. Development of vorinostat-loaded solid lipid nanoparticles to enhance pharmacokinetics and efficacy against multidrug-resistant cancer cells. Pharm. Res. 31(8), 1978–1988 (2014). • Demonstrated the need for improvement of physicochemical and pharmacokinetic properties of vorinostat.
Medline CASGoogle Scholar
17 Tran TH, Chu DT, Truong DH et al. Development of lipid nanoparticles for a histone deacetylases inhibitor as a promising anticancer therapeutic. Drug Deliv. 23(4), 1335–1343 (2014).
MedlineGoogle Scholar
18 Deng C, Jiang Y, Cheng R, Meng F, Zhong Z. Biodegradable polymeric micelles for targeted and controlled anticancer drug delivery: promises, progress and prospects. Nano Today 7(5), 467–480 (2012). • Described the properties of biodegradable polymeric micelles in anticancer therapy.
CASGoogle Scholar
19 Biswas S, Kumari P, Lakhani PM, Ghosh B. Recent advances in polymeric micelles for anti-cancer drug delivery. Eur. J. Pharm. Sci. 83, 184–202 (2016).
Medline CASGoogle Scholar
20 Gao X, Wang S, Wang B et al. Improving the anti-ovarian cancer activity of docetaxel with biodegradable self-assembly micelles through various evaluations. Biomaterials 53, 646–658 (2015).
Medline CASGoogle Scholar
21 Saxena V, Hussain MD. Polymeric mixed micelles for delivery of curcumin to multidrug resistant ovarian cancer. J. Biomed. Nanotechnol. 9(7), 1146–1154 (2013).
Medline CASGoogle Scholar
22 Jin J, Sui B, Gou J et al. PSMA ligand conjugated PCL-PEG polymeric micelles targeted to prostate cancer cells. PLoS ONE 9(11), e112200 (2014).
MedlineGoogle Scholar
23 Mohamed EA, Zhao Y, Meshali MM et al. Vorinostat with sustained exposure and high solubility in poly(ethylene glycol)-b-poly(dl-lactic acid) micelle nanocarriers: characterization and effects on pharmacokinetics in rat serum and urine. J. Pharm. Sci. 101(10), 3787–3798 (2012).
Medline CASGoogle Scholar
24 Ulery BD, Nair LS, Laurencin CT. Biomedical applications of biodegradable polymers. J. Polym. Sci. B Polym. Phys. 49(12), 832–864 (2011).
Medline CASGoogle Scholar
25 Matsumura Y. Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Adv. Drug Deliv. Rev. 63(3), 184–192 (2011).
Medline CASGoogle Scholar
26 Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol. Biol. (Clifton, N.J.) 624, 25–37 (2010).
Medline CASGoogle Scholar
27 Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 63(3), 131–135 (2011).
Medline CASGoogle Scholar
28 Kumari P, Ghosh B, Biswas S. Nanocarriers for cancer-targeted drug delivery. J. Drug Target. 24(3), 179–191 (2016).
Medline CASGoogle Scholar
29 Shuai X, Ai H, Nasongkla N, Kim S, Gao J. Micellar carriers based on block copolymers of poly (ϵ-caprolactone) and poly (ethylene glycol) for doxorubicin delivery. J. Control. Release 98(3), 415–426 (2004).
Medline CASGoogle Scholar
30 Karami Z, Sadighian S, Rostamizadeh K, Parsa M, Rezaee S. Naproxen conjugated mPEG-PCL micelles for dual triggered drug delivery. Mater. Sci. Eng. C Mater. Biol. Appl. 61, 665–673 (2016). •• Described the synthesis of PEG-PCL copolymer.
Medline CASGoogle Scholar
31 Jin X, Wang Y, Tan L et al. An efficient injectable formulation with block copolymer micelles for hydrophobic antitumor candidate-pyridazinone derivatives. Nanomedicine 10(14), 2153–2165 (2015).
CASGoogle Scholar
32 Shi C, Zhang Z, Wang F, Ji X, Zhao Z, Luan Y. Docetaxel-loaded PEO-PPO-PCL/TPGS mixed micelles for overcoming multidrug resistance and enhancing antitumor efficacy. J. Mater. Chem. B 3(20), 4259–4271 (2015).
Medline CASGoogle Scholar
33 Gu G, Xia H, Hu Q et al. PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy. Biomaterials 34(1), 196–208 (2013).
MedlineGoogle Scholar
34 Muthu MS, Avinash Kulkarni S, Liu Y, Feng S-S. Development of docetaxel-loaded vitamin E TPGS micelles: formulation optimization, effects on brain cancer cells and biodistribution in rats. Nanomedicine 7(3), 353–364 (2012).
CASGoogle Scholar
35 Shi L, Song X-B, Wang Y et al. Docetaxel-conjugated monomethoxy-poly (ethylene glycol)-b-poly (lactide)(mPEG-PLA) polymeric micelles to enhance the therapeutic efficacy in oral squamous cell carcinoma. RSC Advances 6(49), 42819–42826 (2016).
CASGoogle Scholar
36 Kaba SI, Egorova EM. In vitro studies of the toxic effects of silver nanoparticles on HeLa and U937 cells. Nanotechnology, Science and Applications 8, 19 (2015).
Medline CASGoogle Scholar
37 Hrzenjak A, Moinfar F, Kremser M-L et al. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol. Cancer 9(1), 1–11 (2010).
MedlineGoogle Scholar
38 Ukawala M, Rajyaguru T, Chaudhari K et al. Investigation on design of stable etoposide-loaded PEG-PCL micelles: effect of molecular weight of PEG-PCL diblock copolymer on the in vitro and in vivo performance of micelles. Drug Deliv. 19(3), 155–167 (2012).
Medline CASGoogle Scholar
39 Mikhail AS, Allen C. Poly(ethylene glycol)-b-poly(ϵ-caprolactone) micelles containing chemically conjugated and physically entrapped docetaxel: synthesis, characterization, and the influence of the drug on micelle morphology. Biomacromolecules 11(5), 1273–1280 (2010).
Medline CASGoogle Scholar
40 Zhang X-Y, Zhang Y-D. Enhanced antiproliferative and apoptosis effect of paclitaxel-loaded polymeric micelles against non-small cell lung cancers. Tumor Biology 36(7), 4949–4959 (2015).
Medline CASGoogle Scholar
41 Wang N, He T, Shen Y et al. Paclitaxel and tacrolimus coencapsulated polymeric micelles that enhance the therapeutic effect of drug-resistant ovarian cancer. ACS Appl. Mater. Interfaces 8(7), 4368–4377 (2016).
Medline CASGoogle Scholar
42 Mohanty C, Acharya S, Mohanty AK, Dilnawaz F, Sahoo SK. Curcumin-encapsulated MePEG/PCL diblock copolymeric micelles: a novel controlled delivery vehicle for cancer therapy. Nanomedicine 5(3), 433–449 (2010).
CASGoogle Scholar
43 Kumari P, Swami MO, Nadipalli SK, Myneni S, Ghosh B, Biswas S. Curcumin delivery by poly(lactide)-based co-polymeric micelles: an in vitro anticancer study. Pharm. Res. 33(4), 826–841 (2016).
Medline CASGoogle Scholar
44 Prajakta D, Ratnesh J, Chandan K et al. Curcumin loaded pH-sensitive nanoparticles for the treatment of colon cancer. J. Biomed. Nanotechnol. 5(5), 445–555 (2009).
Medline CASGoogle Scholar
45 Diao Y-Y, Li H-Y, Fu Y-H et al. Doxorubicin-loaded PEG-PCL copolymer micelles enhance cytotoxicity and intracellular accumulation of doxorubicin in adriamycin-resistant tumor cells. Int. J. Nanomed. 6, 1955–1962 (2011).
Medline CASGoogle Scholar
46 Shi C, Zhang Z, Wang F, Ji X, Zhao Z, Luan Y. Docetaxel-loaded PEO-PPO-PCL/TPGS mixed micelles for overcoming multidrug resistance and enhancing antitumor efficacy. J. Mater. Chem. B 3(20), 4259–4271 (2015).
Medline CASGoogle Scholar
47 Sun L, Deng X, Yang X et al. Co-delivery of doxorubicin and curcumin by polymeric micelles for improving antitumor efficacy on breast carcinoma. RSC Advances 4(87), 46737–46750 (2014).
CASGoogle Scholar
48 Wang F, Chen Y, Zhang D et al. Folate-mediated targeted and intracellular delivery of paclitaxel using a novel deoxycholic acid-O-carboxymethylated chitosan-folic acid micelles. Int. J. Nanomed. 7(145), 325–337 (2012).
Medline CASGoogle Scholar
49 Uehara N, Kanematsu S, Miki H, Yoshizawa K, Tsubura A. Requirement of p38 MAPK for a cell-death pathway triggered by vorinostat in MDA-MB-231 human breast cancer cells. Cancer Lett. 315(2), 112–121 (2012).
Medline CASGoogle Scholar
50 Uehara N, Yoshizawa K, Tsubura A. Vorinostat enhances protein stability of p27 and p21 through negative regulation of Skp2 and Cks1 in human breast cancer cells. Oncol. Rep. 28(1), 105–110 (2012).
Medline CASGoogle Scholar

Vol. 12, No. 1

Supplemental Materials

Metrics

Downloaded 162 times

History

Published online 23 November 2016

Published in print January 2017

Information

Keywords

Financial & competing interests disclosure

This work was supported by the research initiation grant (RIG) from BITS Pilani to authors B Ghosh and S Biswas, grants from the Department of Biotechnology (Bio-CARe scheme, BT/Bio-CARe/07/10003/2013-2014) and the Department of Science & Technology (Fast Track Scheme for Young Scientists, SB/FT/CS-127/2013). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations.

PDF download